Literature DB >> 9696140

Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE.

A R Dinu1, J T Merrill, C Shen, I V Antonov, B L Myones, R G Lahita.   

Abstract

In examining reasons for premature atherosclerosis in systemic lupus erythematosus (SLE), we previously reported low levels of the cholesterol transport protein apolipoprotein A1 (apoA1) in these patients, and specific antibodies to purified apoA1 were identified in the sera of 5 out of 30 lupus patients. The current study was initiated to determine whether these antibodies are common in lupus patients. 520 serum samples from 175 patients with SLE or primary antiphospholipid syndrome (PAPS) were tested for antibodies to purified apoA1. Positive sera were retested for binding to apolipoprotein incorporated into reconstructed nascent or mature high-density lipoprotein (HDL). Autoantibodies to apoA1 were found in 32.5% of patients with SLE and 22.9% of patients with PAPS, associated with the presence of aPL (anti-beta2 glycoprotein-1, anti-beta2 GP1) antibodies. When reconstructed, nascent and mature HDL molecules were compared as antigen-containing environments, positive sera reacted best to apoA1 embedded in mature HDL molecules. This report confirms the high prevalence of antibodies to apoA1 in patients with systemic lupus and suggests a high affinity of these antibodies for mature HDL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696140     DOI: 10.1191/096120398678920262

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  29 in total

Review 1.  Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis.

Authors:  José Delgado Alves; Bruno Grima
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 2.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

Review 3.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

4.  Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies.

Authors:  Sara Kashef; Mohammad Mehdi Ghaedian; Akbar Rajaee; Abbas Ghaderi
Journal:  Rheumatol Int       Date:  2006-08-30       Impact factor: 2.631

Review 5.  Role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity.

Authors:  Eric Champagne; Laurent O Martinez; Pierre Vantourout; Xavier Collet; Ronald Barbaras
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  What causes the antiphospholipid syndrome?

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

7.  Comparison of serum apolipoprotein A-I between Chinese multiple sclerosis and other related autoimmune disease.

Authors:  Bin Zhang; ShuXiang Pu; BinMei Li; JianRui Ying; Xing Wang Song; Cong Gao
Journal:  Lipids Health Dis       Date:  2010-03-29       Impact factor: 3.876

Review 8.  Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus.

Authors:  Allison B Reiss
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 9.  G2A and LPC: regulatory functions in immunity.

Authors:  Janusz H Kabarowski
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-04-19       Impact factor: 3.072

Review 10.  Novel mechanisms of action of the biologicals in rheumatic diseases.

Authors:  Cecilia Beatrice Chighizola; Ennio Giulio Favalli; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.